The Cause of Mitral Regurgitation Determines the Treatment. Here Is How Repair, Replacement, and MitraClip Are Chosen.

2. What It Is

Mitral regurgitation (MR) is incompetence of the mitral valve, allowing backward flow of blood from the left ventricle into the left atrium during systole. Like AR, it creates volume overload of the LV: the LV must pump not only the forward cardiac output but also the regurgitant volume that returns to the LA and then recirculates.

MR is the most prevalent valvular heart disease globally. The Framingham Heart Study identified clinically significant MR in approximately 2% of the population 5 / Solid 69208-9). Echocardiographic MR of any degree is present in a much larger proportion, but clinically significant severe MR accounts for the major disease burden.

Primary vs Secondary MR: the critical distinction

The distinction between primary (degenerative/organic) and secondary (functional) MR is not merely semantic. It determines the mechanism, the natural history, and critically, the evidence base for intervention.

Primary MR (organic): The leaflets or subvalvular apparatus themselves are structurally abnormal:

• Mitral valve prolapse (MVP): the most common cause in developed countries; myxomatous degeneration of the leaflets; posterior leaflet prolapse is more common than anterior
• Flail leaflet: chordal rupture causes a segment of leaflet to flail into the LA; produces severe regurgitation acutely
• Rheumatic MR: leaflet retraction and thickening from post-inflammatory scarring
• Endocarditis: leaflet perforation, vegetation, or chordal destruction

Secondary MR (functional): The leaflets are structurally normal but are tethered or displaced by geometric changes in the LV:

• Ischemic MR: papillary muscle displacement from inferior wall MI restricts leaflet motion (tethers the posterior leaflet)
• Dilated cardiomyopathy-associated MR: annular dilation from global LV dilation displaces the leaflets laterally and apically, preventing coaptation

This distinction matters enormously because the COAPT versus MITRA-FR trials resolved a major clinical controversy in secondary MR treatment, and because surgical versus catheter-based therapy evidence is different for primary versus secondary MR.

3. The Mechanism

Primary MR: the same compensated-volume-overload arc as AR

In chronic severe primary MR, the LV dilates eccentrically to accommodate the regurgitant volume. EF is typically preserved or raised initially (because the LV is ejecting into the low-resistance LA as well as the aorta, artificially raising apparent EF). An EF of 60% in severe MR may represent significantly impaired LV contractility, because the true contractile performance is masked by the easy LA “escape route.”

This has a critical clinical implication: the traditional threshold of EF below 60% for surgery in primary MR (rather than EF below 50% as in most other valve diseases) reflects this masking effect. The 2021 guidelines recommend surgery when EF falls below 60% or LVESD rises above 40 mm (4 cm), even in asymptomatic patients 5 / Solid .

Secondary MR: the tethering mechanism

The posterior leaflet is tethered by its chordal attachments to the papillary muscles. When the inferior wall MI displaces the posterior papillary muscle apically and laterally, the posterior leaflet cannot reach the anterior leaflet during systole: the coaptation point is displaced away from the annular plane into the LV cavity. The resulting incomplete coaptation allows regurgitation from the region of incomplete closure.

In dilated cardiomyopathy, both leaflets are tethered by annular dilation: the enlarged annulus separates the attachment points of both leaflets, while LV sphericity pulls the papillary muscles away from the annular plane.

The regurgitation in secondary MR is a marker of LV disease severity rather than a primary valvular problem. This is why simply correcting the regurgitation (annuloplasty ring alone, without LV remodeling) does not necessarily improve outcomes, and why catheter-based approaches (MitraClip) may achieve MR reduction while also improving forward hemodynamics and LV remodeling in selected patients.

4. How We Diagnose

Auscultation

Primary MR from prolapse or flail: holosystolic murmur (beginning at S1, lasting through systole, ending at S2) at the apex, radiating to the axilla and back. For posterior leaflet prolapse/flail, the jet is directed anteriorly toward the aorta; radiation may be to the right sternal border or even to the carotid. The classic mid-systolic click of MVP precedes the late systolic murmur in classic (non-flail) prolapse.

Acute severe MR (flail leaflet from chordal rupture or endocarditis): the murmur may be surprisingly soft or even absent, because the acute LA pressure rise equalizes rapidly with LV systolic pressure, reducing the pressure gradient driving the regurgitant jet. Clinically: acute pulmonary edema with a soft murmur should raise concern for acute severe MR.

Echocardiography

Complete MR assessment requires:

• MR severity grading (vena contracta width, regurgitant orifice area by proximal isovelocity surface area (PISA), regurgitant volume)
• Identification of mechanism (prolapse, flail, tethering, annular dilation)
• LV dimensions and EF
• LA size (dilated LA from chronic raised LA pressure)
• Pulmonary artery pressure estimate
• For secondary MR: assessment of LV geometry, wall motion abnormalities, and tethering severity

Transesophageal echo (TEE): essential pre-operative for repair suitability assessment (anatomy of the prolapsing segment, chordal anatomy, annular dimensions) and for intra-operative guidance during repair.

5. The Evidence

Primary MR: repair-not-replace principle

The landmark principle in primary MR surgery is repair over replacement. The observational data across multiple surgical centers supports this: mitral valve repair (preserving the native leaflet, chordal, and papillary muscle apparatus) produces better long-term outcomes than replacement 5 / Solid 00650-0; multiple center series). Repair preserves LV geometry (the chordal attachments to the papillary muscles contribute to LV geometry), avoids prosthetic valve complications (thromboembolism risk of mechanical, structural deterioration of bioprosthetic), and does not require long-term anticoagulation.

The 2021 ACC/AHA guidelines recommend repair over replacement when feasible by an experienced operator 5 / Solid . “Experienced operator” is defined as performing at least 25 mitral valve repair cases per year; repair rates above 95% at high-volume centers for posterior leaflet prolapse, the most common and most surgically accessible lesion.

For anterior leaflet prolapse (P2 is posterior, A2 is anterior), repair is technically more demanding but still preferred at experienced centers.

EVEREST II: MitraClip vs surgery for primary MR (2011)

The MitraClip (Abbott) is a catheter-delivered clip that grasps the mitral leaflets and creates a double-orifice mitral valve (the “bow tie” repair), reducing MR without surgery.

EVEREST II enrolled 279 patients with moderate-to-severe or severe primary or secondary MR and randomized them to MitraClip versus surgery 5 / Solid . MitraClip was less effective at reducing MR (residual severe MR in 21% at 12 months versus 20% for surgery), but had lower 30-day procedural complications. Surgery was more effective for complete MR abolition.

Interpretation: MitraClip is inferior to surgery for the treatment of primary MR in patients who are good surgical candidates. Its role in primary MR is in patients who are high-surgical-risk and cannot safely undergo open repair.

COAPT: MitraClip for secondary MR in HFrEF (2018)

COAPT is the most important trial in the secondary MR story. COAPT enrolled 614 patients with severe secondary MR (EROA above 0.20 cm2, regurgitant volume above 30 mL) and HFrEF (EF 20-50%), who remained symptomatic on maximally tolerated GDMT 5 / Solid .

Results: MitraClip reduced all hospitalizations for HF by 47% (RR 0.53, 95% CI 0.40-0.70) and all-cause mortality by 29% (RR 0.62, 95% CI 0.46-0.82) at two years. These were striking results in a population with otherwise poor prognosis.

The population: “COAPT-eligible” requires severe MR on maximally tolerated GDMT. The GDMT was assessed by a central GDMT evaluation team. Patients who could be uptitrated further were not enrolled until they were maximized. This detail matters.

MITRA-FR: the contradictory trial (2018)

MITRA-FR enrolled 307 patients with severe secondary MR and HFrEF and randomized them to MitraClip plus GDMT versus GDMT alone 5 / Solid . At one year, MitraClip provided no benefit over GDMT alone for the composite of all-cause death or unplanned HF hospitalization (54.6% vs 51.3%, p = 0.53).

How can two trials enrolling similar patients produce opposite results? The reconciliation (Lancet 2019, Grayburn PA, et al.; 10.1016/S0140-6736(19)30124-5): COAPT enrolled patients with “proportionate” severe MR (the MR was severe relative to the LV size: the LV was not disproportionately dilated compared to the MR severity). MITRA-FR enrolled patients with more “disproportionate” MR (very dilated LVs with secondary MR that was less severe relative to LV size). The implication: MitraClip benefits secondary MR patients in whom MR is a primary driver of hemodynamic deterioration, not just a marker of LV disease severity.

The current clinical standard: MitraClip is reasonable for patients with secondary MR who remain symptomatic despite maximized GDMT, meet COAPT eligibility criteria (EROA above 0.20 cm2, regurgitant volume above 30 mL, EF 20-50%), and have COAPT-like anatomy 5 / Solid .

RESHAPE-HF2: MitraClip in HFrEF with secondary MR (2024)

RESHAPE-HF2 enrolled patients with HFrEF and moderate-to-severe secondary MR and showed MitraClip reduced HF hospitalization and cardiovascular death 4 / Promising . This adds further support for MitraClip in the secondary MR-HFrEF population but does not change the COAPT-eligible selection criteria.

Sex differences in mitral regurgitation

Women and men experience mitral valve prolapse differently. The Framingham Heart Study showed MVP has equal prevalence in men and women 5 / Solid , but women with MVP develop severe MR at lower rates than men. When women do require surgery, repair rates are slightly lower and replacement rates slightly higher, partly due to smaller annular size and more complex repair anatomy.

Women with severe primary MR are referred for surgery at lower rates and at later stages of LV dysfunction compared to men, a disparity documented in multiple registry analyses 5 / Solid . This is a quality-of-care gap, not a biological difference.

6. The Patient Experience

The nurse from the North Shore represents the typical primary MR patient who has lived with their murmur for decades without understanding that the murmur was a window into a progressive process. The gradual adaptation to worsening exercise capacity, the normalization of fatigue, the reluctance to report symptoms are common patterns in patients with slowly progressive valve disease.

Symptom elicitation matters. Asking “do you have shortness of breath” may get a denial. Asking “how does your exercise capacity now compare to two years ago?” elicits the comparison that reveals functional decline. The NYHA functional classification does not always match the echocardiographic severity, because patients self-limit activity to avoid triggering symptoms.

Post-surgical recovery for mitral repair: sternotomy approach requires 6-8 weeks recovery. Minimally invasive (right thoracotomy, mini-sternotomy) approaches are available at high-volume centers, with 2-4 week recovery times. Robotic mitral repair, available at selected centers including Northwestern Memorial Hospital (Chicago), University of Chicago, and Rush University Medical Center, provides the smallest incision and fastest recovery.

For MitraClip patients (secondary MR, high surgical risk), the procedure is catheter-based: femoral vein access, transseptal puncture to cross to the left atrium, and clip deployment. Hospital stay is 1-2 days. Recovery is rapid but MR reduction is partial in most cases; residual mild-to-moderate MR is expected and acceptable.

AF is a common comorbidity in severe MR: the chronically raised LA pressure dilates the LA and promotes AF. For patients undergoing mitral valve surgery with a history of AF or significantly dilated LA, a concomitant Maze procedure (surgical AF ablation) can be performed, reducing post-operative AF burden.

7. Decisions and Trade-Offs

Timing of surgery for primary MR

The guideline thresholds (Class 1 recommendations for surgical repair):

• Symptomatic severe primary MR with EF above 30%: surgery recommended
• Asymptomatic severe primary MR with EF below 60% or LVESD above 40 mm: surgery recommended
• Asymptomatic severe primary MR with preserved EF and high likelihood of durable repair at experienced center: surgery reasonable (Class 2a)

The last indication is the most debated. Should an asymptomatic patient with severe primary MR, EF 67%, LVESD 38 mm, undergo surgery now if an experienced operator at a high-volume center quotes a 96% repair probability? The data supports this: earlier repair prevents LV dysfunction and reduces AF risk from progressive LA dilation. Operative mortality at high-volume mitral repair centers is below 0.5% for isolated repair 5 / Solid .

Repair suitability assessment

Not all prolapse anatomy is equally repairable. The most favorable anatomy for repair: isolated P2 segment prolapse with a good-quality posterior leaflet and a non-dilated annulus. The least favorable: calcified annulus, extensive rheumatic thickening, bileaflet prolapse with complex anatomy, or endocarditis-related leaflet destruction. The decision to perform repair vs replacement requires a skilled surgeon’s direct assessment at the time of operation.

Sending a patient to a center that performs 10 mitral repairs per year versus 200 mitral repairs per year makes a measurable difference in repair rates, reoperation rates, and mortality.

Secondary MR: surgery vs MitraClip vs neither

For secondary MR in the setting of HFrEF on maximally uptitrated GDMT:

• MitraClip if COAPT-eligible (strict criteria; avoid applying to MITRA-FR-type patients)
• Surgery is not routinely recommended for secondary MR because the valve itself is normal; annuloplasty ring alone has high recurrence rates 5 / Solid
• For patients with severe secondary MR undergoing CABG for concurrent revascularization, concomitant mitral annuloplasty is reasonable

Clinical Synthesis

Mitral regurgitation, both primary and secondary, sits at the center of the clinical mission: the primary MR patient who has been monitored for 40 years without a clear conversation about thresholds, and the secondary MR patient with HFrEF who is on below-target GDMT and therefore not even COAPT-eligible.

A structured cardiovascular assessment for patients with known MR establishes the current severity, the LV dimensions, the EF trajectory, and the referral pathway. For patients with severe primary MR approaching guideline thresholds (EF approaching 60%, LVESD approaching 40 mm), proactive surgical consultation at a high-volume repair center is the standard. Stop Dying Early facilitates that referral before the patient decompensates.

For patients with secondary MR and HFrEF: the first step is maximizing GDMT, because MitraClip’s benefit was demonstrated on top of maximally tolerated background therapy. An structured remote monitoring patient with secondary MR who is not on all four drug classes is not yet at the starting line for the COAPT protocol.

The nurse from the North Shore underwent robotic mitral repair at Northwestern Memorial. Repair was successful: residual MR was trace. She was back to full nursing floor shifts at week six. Her six-month echo showed EF 62% and LVESD 3.5 cm. The remodeling reversed.

She now screens every one of her heart failure patients for mitral valve disease at admission. She understands what the murmur means.

For the heart failure patient whose murmur turns out to be severe secondary MR: the murmur is the signal. The ventricle is the source. The therapy targets both. GDMT and MitraClip are not competing strategies; they are a sequence. The drug comes first. The device, if the patient remains COAPT-eligible, may come after.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.